Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) fell 9.3% during trading on Monday . The company traded as low as $9.74 and last traded at $9.81. 996,717 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 1,666,032 shares. The stock had previously closed at $10.82.
Ginkgo Bioworks Trading Down 1.0 %
The company has a fifty day simple moving average of $11.53. The company has a market capitalization of $518.17 million, a PE ratio of -0.69 and a beta of 1.16.
Institutional Investors Weigh In On Ginkgo Bioworks
Large investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Ginkgo Bioworks by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock worth $412,000 after purchasing an additional 5,746 shares in the last quarter. Shay Capital LLC purchased a new stake in Ginkgo Bioworks in the fourth quarter worth approximately $223,000. Point72 Asset Management L.P. bought a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $980,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Ginkgo Bioworks during the fourth quarter worth approximately $342,000. Finally, Millennium Management LLC lifted its holdings in shares of Ginkgo Bioworks by 357.4% in the 4th quarter. Millennium Management LLC now owns 670,065 shares of the company's stock worth $6,580,000 after acquiring an additional 523,571 shares during the last quarter. Hedge funds and other institutional investors own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
